{"id":1270,"date":"2015-07-06T15:01:00","date_gmt":"2015-07-06T15:01:00","guid":{"rendered":"https:\/\/onltherapeutics.com\/test\/?p=1270"},"modified":"2026-01-28T22:06:59","modified_gmt":"2026-01-28T22:06:59","slug":"onl-therapeutics-promotes-new-lead-drug-expands-clinical-program","status":"publish","type":"post","link":"https:\/\/onltherapeutics.com\/test\/2015\/07\/06\/onl-therapeutics-promotes-new-lead-drug-expands-clinical-program\/","title":{"rendered":"ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program"},"content":{"rendered":"\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\" style=\"padding-right:0;padding-left:0\">ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program<\/h3>\n\n\n\n<p><strong>Xconomy Detroit \u2013 7\/6\/15<\/strong>&nbsp;<strong>by Sarah Schmid<\/strong>&nbsp;ONL Therapeutics, a University of Michigan spin-out working on sight-preserving therapies&nbsp;for retinal diseases, announced that it has changed course in its drug development program. The company has promoted a new lead drug candidate and has expanded its planned clinical studies to include both dry and wet forms of age-related macular degeneration (AMD).<\/p>\n\n\n\n<p><a rel=\"noreferrer noopener\" href=\"http:\/\/www.xconomy.com\/detroit\/2015\/07\/06\/onl-therapeutics-promotes-new-lead-drug-expands-clinical-program\/\" target=\"_blank\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-blue-color\">Read the Article<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program Xconomy Detroit \u2013 7\/6\/15&nbsp;by Sarah Schmid&nbsp;ONL Therapeutics, a University of Michigan spin-out working on sight-preserving therapies&nbsp;for retinal diseases, announced that it has changed course in its drug development program. The company has promoted a new lead drug candidate and has expanded its planned clinical studies to [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"blank","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[5,6],"tags":[],"class_list":["post-1270","post","type-post","status-publish","format-standard","hentry","category-news","category-onl-therapeutics-news"],"featured_image_urls_v2":{"full":"","thumbnail":"","medium":"","medium_large":"","large":"","1536x1536":"","2048x2048":"","gform-image-choice-sm":"","gform-image-choice-md":"","gform-image-choice-lg":""},"post_excerpt_stackable_v2":"<p>ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program Xconomy Detroit \u2013 7\/6\/15&nbsp;by Sarah Schmid&nbsp;ONL Therapeutics, a University of Michigan spin-out working on sight-preserving therapies&nbsp;for retinal diseases, announced that it has changed course in its drug development program. The company has promoted a new lead drug candidate and has expanded its planned clinical studies to include both dry and wet forms of age-related macular degeneration (AMD). Read the Article<\/p>\n","category_list_v2":"<a href=\"https:\/\/onltherapeutics.com\/test\/category\/news\/\" rel=\"category tag\">News<\/a>, <a href=\"https:\/\/onltherapeutics.com\/test\/category\/onl-therapeutics-news\/\" rel=\"category tag\">News Items<\/a>","author_info_v2":{"name":"ONL Therapeutics","url":"https:\/\/onltherapeutics.com\/test\/author\/onl-therapeutics\/"},"comments_num_v2":"0 comments","_links":{"self":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/1270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/comments?post=1270"}],"version-history":[{"count":1,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/1270\/revisions"}],"predecessor-version":[{"id":1271,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/posts\/1270\/revisions\/1271"}],"wp:attachment":[{"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/media?parent=1270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/categories?post=1270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/onltherapeutics.com\/test\/wp-json\/wp\/v2\/tags?post=1270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}